Searchable abstracts of presentations at key conferences in endocrinology

ea0029p873 | Endocrine tumours and neoplasia | ICEECE2012

Hypoglycemia by insulinoma: for the purposes of a case

Jorge G. , Nogueira C. , Esteves C. , Neves C. , Queiros J. , Oliveira M. , Pardal J. , Carvalho D.

Clinical caseIntroduction: Insulinoma is a rare disorder with an estimated incidence of 1 case per 250 000 people per year.Case report: 37 years old female, with a history of irritable bowel syndrome, dyslipidemia and kidney stones. In December 2010, she developed a headache, dizziness and visual disturbances, predominantly in the evening and amnesia for some of the episodes. Initially interpreted as peripheral vertiginous syndrome, because of recurrence...

ea0029p1658 | Thyroid (non-cancer) | ICEECE2012

Autoimmune thyroid disease and cardiovascular risk factors

Neves C. , Esteves C. , Pereira M. , Dias C. , Palmares C. , Sokhatska O. , Carvalho D. , Delgado L. , Medina J.

Aims: To examine whether GravesÂ’ disease (GD) and Hashimoto thyroiditis (HT) are associated with insulin resistance (IR) and other cardiovascular risk factors. Patients and methods: We analyzed 479 patients with autoimmune thyroid disease, 354 (74%) with HT and 126 (26%) with GD, 94% woman, with a mean age of 46±16 years. The patients in both groups were properly treated in order to normalize TSH, FT3 and FT4 levels. We recorded thyroid function...

ea0029p799 | Endocrine tumours and neoplasia | ICEECE2012

Neuroendocrine Tumor with Clinical Characteristics of Insulinoma

Menezes J. , Rodrigues E. , Nogueira C. , Esteves C. , Jorge G. , Matos M. , Graca L. , Pinheiro J. , Pinheiro Loureiro , Lopes J. , Costa J. , Costa Maia , Carvalho D.

Introduction: Insulinomas are almost always located in the pancreas and are usually small. The peak incidence is from the third to fifth decade of life, with females being slightly more frequently affected. The average duration of neuroglycopenic symptoms prior to diagnosis is often prolonged, being more than 5 years in 20% of patients.Case presentation: Female, 52 years old, medical history notable for hypertension, dislipidemia and Graves disease. She ...

ea0070ep558 | Hot topics (including COVID-19) | ECE2020

SGLT-2 inhibitors as adjunctive therapy in type 1 diabetes: Short experience from a center

Salazar Daniela , Esteves César , Carvalho Davide

Background: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were recently approved as adjunctive treatment for type 1 diabetes (T1D), contributing to better glycemic control, cardiovascular and renal protection. Aim: access the efficacy and safety of these antidiabetic agents in selected T1D patients.Methods: Evaluation of medical records of T1D patients starting SGLT-2 inhibitors between August 2018 and October 2019.Results: 24...

ea0029p693 | Diabetes | ICEECE2012

Variations in insulin daily dose and weight with continuous subcutaneous insulin infusion therapy

Belo S. , Esteves C. , Pereira M. , Neves C. , Carvalho D.

Introduction: Intensive diabetes type 1 management can be achieved either with multiple daily insulin injection therapy or with continuous subcutaneous insulin infusion (CSII). The former is becoming increasingly popular do to its positive effects on glycemic control.Objectives: Evaluate the evolution of total daily insulin dose (TDID) and weight on patients with CSII.Methods: Patients with CSII of our department were included. Dat...

ea0029p718 | Diabetes | ICEECE2012

Gender differences in metabolic outcomes of continuous subcutaneous insulin infusion therapy

Esteves C. , Neves M. , Belo S. , Pereira M. , Sousa Z. , Carvalho D.

Introduction: The continuous subcutaneous insulin infusion (CSII) is an alternative to multiple daily injection therapy in type 1 diabetes and its use is increasingly common due to the beneficial effects on the glycemic control of the patient.Aims: To find differences on outcomes of CSII therapy between genders. Patients and methods: Patients on CSII therapy in our department were included in the study and we recorded outcomes regarding the following set...

ea0029p396 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Central diabetes insipidus: about two clinical cases

Nogueira C. , Matos M. , Esteves C. , Jorge G. , Couto J. , Neves C. , Queiros J. , Vinha E. , Bernardes I. , Carvalho D.

Introduction: Central diabetes insipidus (CDI) is produced by the destruction of the magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei which results in decreased arginine vasopressin (AVP) synthesis and secretion.Case report 1: Forty-five year old female, previously healthy, was observed in April 2011 complaining of polydipsia, polyuria, nocturia and weight loss since January. Diabetes mellitus (DM) was excluded and she was ...

ea0026p720 | Diabetes (epidemiology, pathophysiology) | ECE2011

Diagnostic criteria for glucose homeostasis abnormalities in obese patients: are there any differences?

Mesquita J , Rodrigues P , Nogueira C , Belo S , Esteves C , Matos M J , Varela A , Freitas P , Queiros Joana , Correia Flora , Oliveira Bruno , Ferreira de Almeida Manuel , Guimaraes Joao Tiago , Medina Jose Luis , Carvalho Davide

Introduction: The course of type 2 diabetes mellitus (DM) is insidious and, before its development, other glucose homeostasis abnormalities can be detected: impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevation of HbA1c.Aims: To compare the prevalence of glucose homeostasis abnormalities in obese patients, using diagnostic criteria of American Diabetes Association (ADA) 2009, ADA 2010 and International Diabetes Federation (IDF) 2...